ARCHIVES

Inhibitor Reduces Spleen Size By 35 Percent or More in Phase III

This article is from The Cancer Letter archive.

Vol. 36 No. 6 | June 28, 2013

Download PDF Visit The Full Archive

Related Articles

In Brief: Progress Reported In NCI-FDA Fight Over New Drug Tests, Epidemiology Branch Reorganized

December 12, 1975

The March To Deliver Message Of Funding For Cancer Research, Access To Care

September 4, 1998

Benefit Seen In Novel Drug That Treats Gleevec Resistance

April 29, 2005

DeVita Suggest “Overlay Consortium” as Outreach Mechanism for Southern California, Other Areas

September 28, 1984

Monica Bertagnolli To Succeed Schilsky As CALGB Chairman.

November 21, 2008

In Brief: NCAB Committee Recommends Joint NCI/Vendor PDQ Promotion; Frank Schabel Dies In Vienna

September 9, 1983